SCHEMBL365075

SCHEMBL365075

COc1ccc(Cn2cc3c(n2)C(C(C)C)OCC(Br)C3=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 1/20 0.40
PDE1B Q01064 4/20 0.35
PDE1C Q14123 4/20 0.35
PDE1A P54750 2/20 0.35
PDE5A O76074 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
CMA1 P23946 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CASP3 P42574 1/20 0.34
GRM2 Q14416 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HKDC1 Q2TB90 1/20 0.34
SNCA P37840 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6837352 0.87 AADAT (0.41) AADATPDE1BPDE1CPDE1APDE5A
SCHEMBL365921 0.83 AADAT (0.39) AADATPDE1BPDE1CPDE1APDE5A
SCHEMBL366177 0.82 AADAT (0.41) AADATPDE1BPDE1CPDE1ACMA1
SCHEMBL15182502 0.79 AADAT (0.43) AADATPDE1BPDE1CPDE1APDE5A
SCHEMBL364983 0.76 AADAT (0.41) AADATPDE1BPDE1CPDE1APDE5A
SCHEMBL365862 0.73 AADAT (0.42) AADATPDE1BPDE1CPDE1APDE5A
SCHEMBL6837350 0.72 AADAT (0.43) AADATPDE1BPDE1CPDE1ACMA1
SCHEMBL365849 0.72 AADAT (0.44) AADATPDE5APDE4APDE4BPDE4C
SCHEMBL365853 0.72 AADAT (0.45) AADATPDE5APDE4APDE4BPDE4C
SCHEMBL6837143 0.72 AADAT (0.45) AADATPDE5APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 AADAT 837/4885PDE1B 363/4885PDE1C 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.